510 related articles for article (PubMed ID: 19665415)
1. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
[TBL] [Abstract][Full Text] [Related]
2. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
3. Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents.
Harden KA; Cowan PA; Velasquez-Mieyer P; Patton SB
J Am Acad Nurse Pract; 2007 Jul; 19(7):368-77. PubMed ID: 17680902
[TBL] [Abstract][Full Text] [Related]
4. Metformin improves skin capillary reactivity in normoglycaemic subjects with the metabolic syndrome.
Kraemer de Aguiar LG; Laflor CM; Bahia L; Villela NR; Wiernsperger N; Bottino DA; Bouskela E
Diabet Med; 2007 Mar; 24(3):272-9. PubMed ID: 17263761
[TBL] [Abstract][Full Text] [Related]
5. The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study.
Andreadis EA; Katsanou PM; Georgiopoulos DX; Tsourous GI; Yfanti GK; Gouveri ET; Diamantopoulos EJ
Exp Clin Endocrinol Diabetes; 2009 Apr; 117(4):175-80. PubMed ID: 19053032
[TBL] [Abstract][Full Text] [Related]
6. Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance.
Eriksson JG; Lehtovirta M; Ehrnström B; Salmela S; Groop L
J Intern Med; 2006 Jun; 259(6):553-60. PubMed ID: 16704555
[TBL] [Abstract][Full Text] [Related]
7. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
[TBL] [Abstract][Full Text] [Related]
8. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance.
de Aguiar LG; Bahia LR; Villela N; Laflor C; Sicuro F; Wiernsperger N; Bottino D; Bouskela E
Diabetes Care; 2006 May; 29(5):1083-9. PubMed ID: 16644641
[TBL] [Abstract][Full Text] [Related]
9. Effect of orlistat on cardiovascular disease risk in obese adults.
Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID
Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
[TBL] [Abstract][Full Text] [Related]
10. BIGPRO (biguanides and the prevention of the risk of obesity): study design. A randomized trial of metformin versus placebo in the correction of the metabolic abnormalities associated with insulin resistance.
Fontbonne A; André P; Eschwège E
Diabete Metab; 1991 May; 17(1 Pt 2):249-54. PubMed ID: 1936485
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of metabolic syndrome among Filipino adults aged 20 years and over.
Tanchoco CC; Cruz AJ; Duante CA; Litonjua AD
Asia Pac J Clin Nutr; 2003; 12(3):271-6. PubMed ID: 14505989
[TBL] [Abstract][Full Text] [Related]
12. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of metformin in normoglycemic morbidly obese adolescents.
Kay JP; Alemzadeh R; Langley G; D'Angelo L; Smith P; Holshouser S
Metabolism; 2001 Dec; 50(12):1457-61. PubMed ID: 11735093
[TBL] [Abstract][Full Text] [Related]
14. Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial.
Zinman B; Harris SB; Gerstein HC; Young TK; Raboud JM; Neuman J; Hanley AJ
Diabetes Obes Metab; 2006 Sep; 8(5):531-7. PubMed ID: 16918588
[TBL] [Abstract][Full Text] [Related]
15. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö Preventive Trial with diet and exercise.
Eriksson KF; Lindgärde F
Diabetologia; 1998 Sep; 41(9):1010-6. PubMed ID: 9754818
[TBL] [Abstract][Full Text] [Related]
16. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.
Fontbonne A; Charles MA; Juhan-Vague I; Bard JM; André P; Isnard F; Cohen JM; Grandmottet P; Vague P; Safar ME; Eschwège E
Diabetes Care; 1996 Sep; 19(9):920-6. PubMed ID: 8875083
[TBL] [Abstract][Full Text] [Related]
17. A primary care register for impaired glucose handling (IGH): impact on cardiometabolic profile.
Heald AH; Knapman H; Nair S; Chambers T; Radford D; Rushton T; Anderson SG
Prim Care Diabetes; 2012 Oct; 6(3):213-9. PubMed ID: 22560663
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score.
Tuomilehto J; Lindström J; Hellmich M; Lehmacher W; Westermeier T; Evers T; Brückner A; Peltonen M; Qiao Q; Chiasson JL
Diabetes Res Clin Pract; 2010 Feb; 87(2):267-74. PubMed ID: 20022651
[TBL] [Abstract][Full Text] [Related]
19. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance.
Florez H; Temprosa MG; Orchard TJ; Mather KJ; Marcovina SM; Barrett-Connor E; Horton E; Saudek C; Pi-Sunyer XF; Ratner RE; Goldberg RB;
Diabetes Obes Metab; 2014 Apr; 16(4):326-33. PubMed ID: 24118860
[TBL] [Abstract][Full Text] [Related]
20. Effects of Portulaca oleracea L. seeds in treatment of type-2 diabetes mellitus patients as adjunctive and alternative therapy.
El-Sayed MI
J Ethnopharmacol; 2011 Sep; 137(1):643-51. PubMed ID: 21718775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
